Active targeting of nanoparticles to tumours can be achieved by conjugation with specific antibodies. Specific active targeting of the HER2 receptor is demonstrated in vitro and in vivo with a subcutaneous MCF-7 breast cancer mouse model with trastuzumab-functionalized gold nanoparticles. The number of attached antibodies per nanoparticle was precisely controlled in a way that each nanoparticle was conjugated with either exactly one or exactly two antibodies. As expected, in vitro we found a moderate increase in targeting efficiency of nanoparticles with two instead of just one antibody attached per nanoparticle. However, the in vivo data demonstrate that best effect is obtained for nanoparticles with only exactly one antibody. There is indication that this is based on a size-related effect. These results highlight the importance of precisely controlling the ligand density on the nanoparticle surface for optimizing active targeting, and that less antibodies can exhibit more effect.

Colombo, M., Fiandra, L., Alessio, G., Mazzucchelli, S., Nebuloni, M., De Palma, C., et al. (2016). Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies. NATURE COMMUNICATIONS, 7 [10.1038/ncomms13818].

Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies

COLOMBO, MIRIAM
Co-primo
;
Fiandra, L
Co-primo
;
ALESSIO, GIULIA;MAZZUCCHELLI, SERENA;ROTEM, RANY;PROSPERI, DAVIDE
Ultimo
2016

Abstract

Active targeting of nanoparticles to tumours can be achieved by conjugation with specific antibodies. Specific active targeting of the HER2 receptor is demonstrated in vitro and in vivo with a subcutaneous MCF-7 breast cancer mouse model with trastuzumab-functionalized gold nanoparticles. The number of attached antibodies per nanoparticle was precisely controlled in a way that each nanoparticle was conjugated with either exactly one or exactly two antibodies. As expected, in vitro we found a moderate increase in targeting efficiency of nanoparticles with two instead of just one antibody attached per nanoparticle. However, the in vivo data demonstrate that best effect is obtained for nanoparticles with only exactly one antibody. There is indication that this is based on a size-related effect. These results highlight the importance of precisely controlling the ligand density on the nanoparticle surface for optimizing active targeting, and that less antibodies can exhibit more effect.
Articolo in rivista - Articolo scientifico
Nanoparticles; Nanoscale biophysics; Targeted therapies
English
2016
Colombo, M., Fiandra, L., Alessio, G., Mazzucchelli, S., Nebuloni, M., De Palma, C., et al. (2016). Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies. NATURE COMMUNICATIONS, 7 [10.1038/ncomms13818].
File in questo prodotto:
File Dimensione Formato  
10281-138975.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 3.43 MB
Formato Adobe PDF
3.43 MB Adobe PDF Visualizza/Apri
Colombo_et_al-2016-Nature_Communications.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 5.6 MB
Formato Adobe PDF
5.6 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Colombo_et_al-2016-Nature_Communications.sup-1.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 2.3 MB
Formato Adobe PDF
2.3 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/138975
Citazioni
  • Scopus 111
  • ???jsp.display-item.citation.isi??? 105
Social impact